Wedge Capital Management L L P NC Raises Stock Position in LivaNova PLC (NASDAQ:LIVN)

Wedge Capital Management L L P NC lifted its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 1.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 73,845 shares of the company’s stock after acquiring an additional 1,049 shares during the quarter. Wedge Capital Management L L P NC owned approximately 0.14% of LivaNova worth $3,821,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of LIVN. SG Americas Securities LLC purchased a new position in shares of LivaNova during the third quarter worth approximately $1,672,000. Exchange Traded Concepts LLC purchased a new position in shares of LivaNova during the third quarter worth approximately $555,000. Handelsbanken Fonder AB increased its position in shares of LivaNova by 100.0% during the third quarter. Handelsbanken Fonder AB now owns 17,474 shares of the company’s stock worth $924,000 after acquiring an additional 8,737 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of LivaNova by 20.8% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,176 shares of the company’s stock worth $591,000 after acquiring an additional 1,923 shares during the period. Finally, Strs Ohio increased its holdings in LivaNova by 560.0% during the third quarter. Strs Ohio now owns 9,900 shares of the company’s stock valued at $523,000 after buying an additional 8,400 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

LivaNova Price Performance

Shares of LIVN opened at $55.94 on Thursday. The company has a market cap of $3.02 billion, a price-to-earnings ratio of 174.82 and a beta of 0.89. LivaNova PLC has a twelve month low of $42.75 and a twelve month high of $59.86. The company has a quick ratio of 2.51, a current ratio of 2.95 and a debt-to-equity ratio of 0.44. The company has a 50 day moving average of $53.92 and a two-hundred day moving average of $50.59.

LivaNova (NASDAQ:LIVN) last announced its earnings results on Wednesday, February 21st. The company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.10. LivaNova had a net margin of 1.53% and a return on equity of 12.23%. The company had revenue of $310.10 million during the quarter, compared to the consensus estimate of $287.65 million. During the same period last year, the firm earned $0.81 earnings per share. LivaNova’s revenue was up 12.8% compared to the same quarter last year. As a group, analysts predict that LivaNova PLC will post 3.01 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on LIVN shares. Barclays lifted their price objective on shares of LivaNova from $57.00 to $61.00 and gave the company an “equal weight” rating in a report on Monday, February 26th. Robert W. Baird lifted their price objective on shares of LivaNova from $56.00 to $62.00 and gave the company a “neutral” rating in a report on Thursday, February 22nd. StockNews.com raised shares of LivaNova from a “hold” rating to a “buy” rating in a report on Thursday. Mizuho reissued a “buy” rating and set a $75.00 price objective on shares of LivaNova in a report on Wednesday, March 27th. Finally, Needham & Company LLC reissued a “buy” rating and set a $72.00 price objective on shares of LivaNova in a report on Wednesday, March 20th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, LivaNova currently has a consensus rating of “Moderate Buy” and a consensus target price of $64.40.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.